登录 |  注册 |  忘记密码 |  购卡 |  公司首页
简体   繁體   English
首页 > 中华医学杂志(英文版) >Clinicopathological and prognostic features of hepatoid adenocarcinoma of the stomach

Clinicopathological and prognostic features of hepatoid adenocarcinoma of the stomach

    加入收藏夹      点击:37     被引:1

Background Hepatoid adenocarcinoma of the stomach (HAS) is a rare type of gastric carcinoma, which has its unique clinicopathological features and poorer prognosis than that of the ordinary gastric adenocarcinoma. At present, there is still a lack of understanding about this disease. The current study aimed to summarize and discuss the clinical,pathological, immunohistochemical, and prognostic features of this disease.Methods A total of 20 patients of HAS were retrospectively studied. All the patients were treated in Cancer Hospital of Chinese Academy of Medical Sciences between March 1998 and October 2009. Statistical analysis, including the Kaplan-Meier method, log-rank test and Cox model, were performed by the SPSS 15.0 software.Results Seventeen patients (85%) had at least 1 lymph node metastases; 17 patients (85%) received postoperative immunohistochemical examinations, with an alpha-fetoprotein (AFP) positive rate of 94.1% (16/17); 14 patients had distant metastases (including 12 liver metastases, 1 lung metastasis, and 1 celiac widespread metastases), and one simultaneously had anastomotic recurrence and liver metastases. The overall survival time was 2-99 months (median:12.0 months). The 3-year survival rate of the 20 patients was 17.2%. The 3-year survival rate of patients with complete hepatocyte-like regions and those with both hepatocellular carcinoma and adenocarcinoma regions was 20.0% and 17.5%, respectively (P=0.361). The survival difference among the radical surgery group, palliative surgery group and no surgery group was statistically significant (P=0.022). The Kaplan-Meier method and log-rank test showed that surgery,pTNM stages, and adjuvant chemotherapy were associated with prognosis (P <0.05). The Cox model only confirmed that the pTNM stages and adjuvant chemotherapy had statistical significance for the prognosis of HAS (P<0.05) due to the limited cases.Conclusions HAS is a special type of gastric carcinoma and has a poor prognosis. The pTNM stage is an independent risk factor for HAS. Multidisciplinary therapy, including surgery and chemotherapy, may improve the prognosis of HAS.

作 者 ZHANG Jian-feng;SHI Su-sheng;SHAO Yong-fu;ZHANG Hai-zeng
刊 名 中华医学杂志(英文版)  2011年124卷10期 1470-1476页  科学引文索引(Science Citation Index)收录科学引文索引扩展版(SCI Expanded)收录美国国立医学图书馆Medline数据库收录美国生物学预评数据库(BIOSIS Previews)收录美国《化学文摘》(Chemical Abstracts)收录中国科技论文统计源期刊(中国科技核心期刊)收录
英文期刊名 CHINESE MEDICAL JOURNAL
关键词 hepatoid adenocarcinoma stomach alpha-fetoprotein metastasis prognosis
分类号 S858.23
DOI号 10.3760/cma.j.issn.0366-6999.2011.10.006

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他相关网站。

北京万方数据股份有限公司

万方数据电子出版社

关于我们  |   联系我们  |   网站地图  |   主要产品  |   主要服务

使用帮助  |   服务承诺  |   诚聘英才  |   友情链接  |   知识产权

客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

客服邮箱:yiyao@wanfangdata.com.cn

充值卡购卡热线:400-667-1808

互联网出版许可证 新出网证(京)字042号

互联网药品信息服务资格证书号:(京)-经营性-2011-0017

信息网络传播视听节目许可证

北京市公安局海淀分局备案号:110109081585

京ICP证010071号